Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 13/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323595 | 0.85 | ALDH1A1 (0.58) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL5931108 | 0.85 | FBP1 (0.70) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL184964 | 0.84 | CYP2C9 (0.76) | TDP1FBP1ALDH1A1LMNAALB | |
| Methyl Alcohol SCHEMBL28260710 | 0.82 | CYP2C9 (0.74) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL11049679 | 0.82 | CYP2C9 (0.69) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL4923123 | 0.82 | LMNA (0.61) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL19271872 | 0.81 | EPHX2 (0.68) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL28534045 | 0.81 | EPHX2 (0.68) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL2290886 | 0.80 | ALDH1A1 (0.72) | TDP1FBP1ALDH1A1LMNAALB | |
| SCHEMBL11043925 | 0.80 | FBP1 (0.57) | TDP1FBP1ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | MAPK1 1667/4885TDP1 4334/4885POLB 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.